ISSN: 1307-5888 | E-ISSN: 2757-7392 | Contact
Coronavirus disease 2019 (COVID-19) in autoimmune hepatitis
1Department of Physiology, Harran University, Şanlıurfa, Turkey
2Department of Gastroenterology, Harran University Faculty of Medicine, Sanliurfa, Turkey
Hepatology Forum 2022; 3(2): 68-70 DOI: 10.14744/hf.2022.2022.0012 PMCID: PMC9243756
Full Text PDF


Severe acute respiratory syndrome coronavirus 2 is a highly transmissible and pathogenic virus that leads to coronavirus disease 2019 (COVID-19). The preexisting liver diseases alter the course of COVID-19. Therefore, specific management strategies must be considered in individuals with chronic liver diseases (CLDs) and COVID-19. Autoimmune hepatitis (AIH) is a rare immune-mediated liver disease. Patients with AIH require life-long treatment with immunosuppressive drugs that may increase the risk of poor COVID-19 outcomes. The stage of underlying liver disease is another factor that can affect the clinical outcomes of COVID-19 in patients with AIH. In this review, we aim to provide relevant issues that will be helpful to clinicians in understanding and improving the clinical care for patients with AIH during the pandemic.